食管癌|食管癌和肾癌患者福音!两大重磅免疫疗法再传捷报( 二 )

[1] Bristol Myers Squibb Announces Opdivo (nivolumab) plus Chemotherapy and Opdivo plus Yervoy (ipilimumab) Demonstrate Superior Survival Benefit Compared to Chemotherapy in Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma. Retrieved April 8, 2021, from https://www.businesswire.com/news/home/20210408005274/en
[2] Merck’s KEYTRUDA (pembrolizumab) Demonstrated Superior Disease-Free Survival (DFS) Compared With Placebo as Adjuvant Therapy in Patients With Renal Cell Carcinoma (RCC) Following Surgery. Retrieved April 8, 2021, from https://www.businesswire.com/news/home/20210408005138/en
注:本文旨在介绍医药健康研究进展,不是治疗方案推荐 。如需获得治疗方案指导,请前往正规医院就诊 。
版权说明:本文来自药明康德内容团队,欢迎个人转发至朋友圈,谢绝媒体或机构未经授权以任何形式转载至其他平台 。转载授权请在「药明康德」微信公众号回复“转载”,获取转载须知 。

推荐阅读